Abstract
In colorectal tumours, Wnt pathway genetics continues to be dominated by mutations in the adenomatous polyposis coli (APC) gene. Germline mutations cause familial adenomatous polyposis and at least two-thirds of sporadic colorectal tumours also acquire APC mutations, quite possibly as the initiating events in tumorigenesis. These mutations almost always cause loss of the C-terminal functions of the APC protein – probably involved in microtubule binding, cell polarity and chromosome segregation – and deletion of the SAMP repeats that are important for binding to axin and formation of the beta-catenin phosphorylation complex. The truncated APC proteins are, in general, stable and almost certainly retain some activity in beta-catenin binding. The ‘two hits’ at APC are coselected so as to produce an optimal activation of Wnt signalling (just-right hypothesis). In a minority of colorectal tumours, Wnt activation can occur through mutations that affect phosphorylation sites within exon 3 of beta-catenin, causing protein stabilization. In other tumours, epigenetic transcriptional silencing or mutation of the secreted frizzled-related proteins may modulate Wnt levels. Mutations in the Wnt components AXIN1, AXIN2 and TCF4 have been found in microsatellite-unstable colon cancers, but it is not clear in every case whether these changes are functional. Therapeutic modulation of the Wnt pathway remains an attractive therapeutic possibility for colorectal carcinomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, Espada J et al. (2006). Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25: 4116–4121.
Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT et al. (2002). Inherited variants of MYH associated with somatic G:C → T:A mutations in colorectal tumors. Nat Genet 30: 227–232.
Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ et al. (2005). Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65: 10170–10173.
Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJ et al. (2002). The ‘just-right’ signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 11: 1549–1560.
Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I et al. (2006). Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 342: 1228–1232.
Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P et al. (2004). The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64: 883–888.
Crabtree M, Sieber OM, Lipton L, Hodgson SV, Lamlum H, Thomas HJ et al. (2003). Refining the relation between ‘first hits’ and ‘second hits’ at the APC locus: the ‘loose fit’ model and evidence for differences in somatic mutation spectra among patients. Oncogene 22: 4257–4265.
Crabtree MD, Tomlinson IP, Hodgson SV, Neale K, Phillips RK, Houlston RS . (2002). Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes. Gut 51: 420–423.
Crabtree MD, Tomlinson IP, Talbot IC, Phillips RK . (2001). Variability in the severity of colonic disease in familial adenomatous polyposis results from differences in tumour initiation rather than progression and depends relatively little on patient age. Gut 49: 540–543.
Dihlmann S, Gebert J, Siermann A, Herfarth C, von Knebel Doeberitz M . (1999). Dominant negative effect of the APC1309 mutation: a possible explanation for genotype–phenotype correlations in familial adenomatous polyposis. Cancer Res 59: 1857–1860.
Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R . (2000). The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 60: 3872–3879.
Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA et al. (2000). Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 60: 4366–4371.
Fearnhead NS, Britton MP, Bodmer WF . (2001). The ABC of APC. Hum Mol Genet 10: 721–733.
Fearnhead NS, Wilding JL, Winney B, Tonks S, Bartlett S, Bicknell DC et al. (2004). Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas. Proc Natl Acad Sci USA 101: 15992–15997.
Frayling IM, Beck NE, Ilyas M, Dove-Edwin I, Goodman P, Pack K et al. (1998). The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc Natl Acad Sci USA 95: 10722–10727.
Galiatsatos P, Foulkes WD . (2006). Familial adenomatous polyposis. Am J Gastroenterol 101: 385–398.
Groves C, Lamlum H, Crabtree M, Williamson J, Taylor C, Bass S et al. (2002). Mutation cluster region, association between germline and somatic mutations and genotype–phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am J Pathol 160: 2055–2061.
Gryfe R, Di Nicola N, Lal G, Gallinger S, Redston M . (1999). Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet 64: 378–384.
Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF . (1997). Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 94: 10330–10334.
Johnson V, Volikos E, Halford SE, Eftekhar Sadat ET, Popat S, Talbot I et al. (2005). Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut 54: 264–267.
Knudsen AL, Bisgaard ML, Bulow S . (2003). Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2: 43–55.
Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM et al. (1997). Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17: 79–83.
Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, Bell J et al. (1999). The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's ‘two-hit’ hypothesis. Nat Med 5: 1071–1075.
Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I et al. (2004). Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 74: 1043–1050.
Laurent-Puig P, Beroud C, Soussi T . (1998). APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 26: 269–270.
Li J, Mizukami Y, Zhang X, Jo WS, Chung DC . (2005). Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology 128: 1907–1918.
Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK et al. (2000). Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 26: 146–147.
Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S et al. (1992). Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1: 229–233.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787–1790.
Nugent KP, Phillips RK, Hodgson SV, Cottrell S, Smith-Ravin J, Pack K et al. (1994). Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis. Gut 35: 1622–1623.
Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P . (1997). Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 57: 4624–4630.
Schneikert J, Behrens J . (2006). Truncated APC is required for cell proliferation and DNA replication. Int J Cancer 119: 74–79.
Shimizu Y, Ikeda S, Fujimori M, Kodama S, Nakahara M, Okajima M et al. (2002). Frequent alterations in the Wnt signaling pathway in colorectal cancer with microsatellite instability. Genes Chromosomes Cancer 33: 73–81.
Sieber O, Lipton L, Heinimann K, Tomlinson I . (2003). Colorectal tumourigenesis in carriers of the APC I1307K variant: lone gunman or conspiracy? J Pathol 199: 137–139.
Sieber O, Segditsas S, Knudsen A, Zhang J, Luz J, Rowan A et al. (2006). Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly, but depend on the site of the germline mutation. Gut 55: 1440–1448.
Sieber OM, Lamlum H, Crabtree MD, Rowan AJ, Barclay E, Lipton L et al. (2002). Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or ‘multiple’ colorectal adenomas. Proc Natl Acad Sci USA 99: 2954–2958.
Slattery ML, Samowitz W, Ballard L, Schaffer D, Leppert M, Potter JD . (2001). A molecular variant of the APC gene at codon 1822: its association with diet, lifestyle, and risk of colon cancer. Cancer Res 61: 1000–1004.
Smits R, Kielman MF, Breukel C, Zurcher C, Neufeld K, Jagmohan-Changur S et al. (1999). Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development. Genes Dev 13: 1309–1321.
Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G et al. (1993). Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75: 951–957.
Spirio LN, Samowitz W, Robertson J, Robertson M, Burt RW, Leppert M et al. (1998). Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet 20: 385–388.
Sturt NJ, Gallagher MC, Bassett P, Philp CR, Neale KF, Tomlinson IP et al. (2004). Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 53: 1832–1836.
Su LK, Barnes CJ, Yao W, Qi Y, Lynch PM, Steinbach G . (2000). Inactivation of germline mutant APC alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis. Am J Hum Genet 67: 582–590.
Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD et al. (2004). Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417–422.
Webster MT, Rozycka M, Sara E, Davis E, Smalley M, Young N et al. (2000). Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 28: 443–453.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Segditsas, S., Tomlinson, I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25, 7531–7537 (2006). https://doi.org/10.1038/sj.onc.1210059
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210059
Keywords
This article is cited by
-
The E3 ligase HUWE1 increases the sensitivity of CRC to oxaliplatin through TOMM20 degradation
Oncogene (2024)
-
Colorectal cancer cells secreting DKK4 transform fibroblasts to promote tumour metastasis
Oncogene (2024)
-
Novel read through agent: ZKN-0013 demonstrates efficacy in APCmin model of familial adenomatous polyposis
Journal of Molecular Medicine (2023)
-
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Signal Transduction and Targeted Therapy (2022)
-
OCC-1D regulates Wnt signaling pathway: potential role of long noncoding RNA in colorectal cancer
Molecular Biology Reports (2022)